TICKERNERD
Menu
ADPTADPTHealthcare · Diagnostics & Research

ADPT Stock Forecast: Adaptive Biotechnologies Corp. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$27
+3.60% on the day

The 8 Wall Street analysts covering Adaptive Biotechnologies Corp. hold a median 12-month price target of $32 — +19.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 3 Nov 2026 — in the upper half.

Market cap
$4.1B
Ticker Nerd rank
69/ 100
Median analyst target
$32
Analysts covering
8
Revenue$71.6M+21.5% y/y
Operating income−$15.8M
Net income−$39.9M
Free cash flow−$7.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.8%
1M
−5.7%
YTD
+64.6%
1Y
+58.0%
From 52W high
−10.4%
From 52W low
+115.4%
$12
$30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ADPT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Adaptive Biotechnologies Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Nov 2026
69/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
92
Growth
83
Quality
75
Revisions
70
Accruals
62
Value
50
Volatility
49
Size
26
Issuance
14

Momentum (92): The shares have been drifting up relative to others.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ADPT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ADPT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30$35Jan 26Apr 26Jul 26Oct 26ADPTHigh $35Median $32Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $21Median $32High $35

The green dot is the last close — the median target sits +19.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Oct 2026Morgan StanleyMaintainsEqual-Weight$22 → $27
13 Oct 2026TD CowenMaintainsBuy$28 → $32
1 Oct 2026GuggenheimMaintainsBuy$25 → $32
1 Oct 2026GuggenheimMaintainsBuy—
29 Sept 2026Goldman SachsInitiatesBuy$35
29 Sept 2026Goldman SachsInitiatesBuy—
22 Sept 2026BTIGMaintainsBuy$25 → $34
22 Sept 2026BTIGMaintainsBuy—
4 Aug 2026Piper SandlerMaintainsOverweight$20 → $28
4 Aug 2026Piper SandlerMaintainsOverweight—
30 July 2026BTIGMaintainsBuy—
30 July 2026BTIGMaintainsBuy$24 → $25
30 July 2026GuggenheimMaintainsBuy—
30 July 2026GuggenheimMaintainsBuy$22 → $25
30 July 2026Morgan StanleyMaintainsEqual-Weight$20 → $22
30 July 2026Morgan StanleyMaintainsEqual-Weight—
30 July 2026TD CowenMaintainsBuy—
30 July 2026TD CowenMaintainsBuy$25 → $28
9 July 2026Morgan StanleyMaintainsEqual-Weight$18 → $20
9 July 2026Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ADPT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ADPT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Adaptive Biotechnologies Corp. returned +58.0% against +14.8% for the S&P 500, dividends included.

ADPT vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26ADPTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ADPT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Adaptive Biotechnologies Corp. (ADPT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−66.2×

Cheaper than 99% of US stocks

Price / sales
13.4×

Cheaper than 11% of US stocks

Price / book
28.8×

Cheaper than 3% of US stocks

EV / EBITDA
−191.0×

Cheaper than 97% of US stocks

Growth & margins
Revenue growth (YoY)
21.5%

Higher than 71% of US stocks

Earnings growth (YoY)
—
Gross margin
71.8%

Higher than 84% of US stocks

Operating margin
−22.0%

Higher than 21% of US stocks

Net margin
−20.7%

Higher than 15% of US stocks

Returns & dividend
Return on equity
−38.8%

Higher than 25% of US stocks

Return on assets
−4.1%

Higher than 33% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Adaptive Biotechnologies Corp. (ADPT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Adaptive Biotechnologies Corp. has a market value of $4.1B and an enterprise value of $4.1B.

  • Revenue in the twelve months to 30 June 2026: $308.1M. The latest quarter grew 21.5% year on year.

  • Net income over the same four quarters: −$64.0M, a −20.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.41.

  • Free cash flow in the twelve months to 30 June 2026: −$24.0M.

  • Shares outstanding: 159.1M.

  • Trailing P/E: −66.2×; forward P/E: −143.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Adaptive Biotechnologies Corp. employs 624 people — $494K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

ADPT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
ADPTAdaptive Biotechnologies Corp.$4.1B69
VCYTVeracyte, Inc.$4.0B93
CDNACareDx, Inc.$4.6B89
SHCSotera Health Co.$4.6B86
BLLNBillionToOne, Inc.$5.2B16
RDNTRadNet, Inc.$5.7B40
GRALGRAIL, Inc.$6.2B40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Adaptive Biotechnologies Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ADPT news & analysis

Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research · 5 Nov 2026neutral

Zacks Investment Research says Adaptive Biotechnologies’ Q3 headline figures provide a view of its performance for the quarter ended September 2026, and highlights comparing key metrics with Wall Street estimates and year-ago actuals.

Why it matters — The comparisons give ADPT watchers context for evaluating the quarter’s results against expectations and prior-year performance.

Adaptive Biotechnologies Q3 Earnings Call Highlights

MarketBeat · 5 Nov 2026positive

Adaptive Biotechnologies reported third-quarter net income and raised its full-year revenue outlook for its minimal residual disease business. The company said demand for its clonoSEQ cancer testing service increased in clinical care and drug development.

Why it matters — ADPT watchers may note the reported income, higher revenue outlook for the business, and increased demand for clonoSEQ.

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

GlobeNewsWire · 4 Nov 2026positive

Adaptive Biotechnologies reported financial results for the quarter ended September 30, 2026. The company said it achieved total company profitability ahead of expectations and delivered 44% growth in core MRD revenue in Q3.

Why it matters — The reported profitability and core MRD revenue growth provide ADPT watchers with updates on the company's quarterly financial performance.

Adaptive Biotechnologies: Getting Paid Every Step Of The Way To A Myeloma Cure

Seeking Alpha · 27 Oct 2026positive

The article says new NCCN guidelines and IMS cure definitions support clonoSEQ’s role in long-term myeloma MRD monitoring. MRD revenue rose 33% year over year to $66.2 million, while the company reported higher test volumes and clinical ASP, a 14% adjusted EBITDA margin, and financing changes that it says provide over five years of runway.

Why it matters — The developments and reported growth in MRD testing, alongside changes to revenue sharing and debt financing, are relevant to ADPT’s commercial progress and financial position.

Alger Small Cap Focus Fund Q3 2026 Portfolio Update

Seeking Alpha · 23 Oct 2026positive

Adaptive Biotechnologies was among the top contributors to the Alger Small Cap Focus Fund’s performance in the third quarter of 2026.

Why it matters — The update identifies ADPT as a positive contributor to this fund’s quarterly performance.

FAQ

Frequently asked questions about ADPT stock

What is the ADPT stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Adaptive Biotechnologies Corp. have a median 12-month price target of $32, with estimates ranging from $21 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ADPT stock a buy right now?

Of the 8 analysts covering Adaptive Biotechnologies Corp., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Adaptive Biotechnologies Corp. 69 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ADPT?

As at 3 Nov 2026, Adaptive Biotechnologies Corp. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).

Will ADPT stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +19.7% from the last close, and Ticker Nerd's factor model ranks Adaptive Biotechnologies Corp. 69 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ADPT stock forecast for 2030?

No analyst covering Adaptive Biotechnologies Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $35 over the next 12 months.

How has ADPT stock performed over the past year?

Adaptive Biotechnologies Corp. returned +58.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Adaptive Biotechnologies Corp. do?

Adaptive Biotechnologies Corporation Common Stock represents the equity of Adaptive Biotechnologies Corporation, a commercial-stage biotechnology company focused on immune medicine. The company develops products and services that use immunosequencing, proprietary chemistry, computational biology, and machine learning to analyze the adaptive immune system and support clinical diagnostics, life sciences research, and drug discovery.

What is the latest news on ADPT?

The most recent item we track (Zacks Investment Research, 5 Nov 2026): "Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates". Zacks Investment Research says Adaptive Biotechnologies’ Q3 headline figures provide a view of its performance for the quarter ended September 2026, and highlights comparing key metrics with Wall Street estimates and year-ago actuals.

Company

About Adaptive Biotechnologies Corp.

Adaptive Biotechnologies Corporation Common Stock represents the equity of Adaptive Biotechnologies Corporation, a commercial-stage biotechnology company focused on immune medicine. The company develops products and services that use immunosequencing, proprietary chemistry, computational biology, and machine learning to analyze the adaptive immune system and support clinical diagnostics, life sciences research, and drug discovery. Its portfolio includes clonoSEQ, a test used to detect and monitor minimal residual disease in cancer patients, along with immunoSEQ-based offerings for immune profiling and research applications. Adaptive Biotechnologies serves healthcare providers, pharmaceutical partners, researchers, and biotech collaborators across oncology and broader immunology-related markets. Headquartered in Seattle, Washington, the company plays a specialized role in translating immune system data into tools for disease detection and treatment support.

CEO Mr. Chad M. Robins M.B.A. · 624 employees · United States · https://www.adaptivebiotech.com